CureAge Therapeutics Secures ยฃ500,000 to Advance its NF1 Genetic Therapy
Innovate UK co-funded project unites leading UK clinical, patient advocacy, and Cell and Gene Therapy partners to benchmark CureAge's prototype against current standard of care.
โ
CureAge Therapeutics has launched its first Innovate UK co-funded project, backed by ยฃ500,000 in combined grant and matched investment, to advance preclinical development of its genetic therapy for neurofibromatosis type 1 (NF1).
โ
A Collaborative Benchmark Study
The project brings together CureAge, Dr. Josh Hersheson (NF1 clinical lead, Guy's and St Thomas' NHS Foundation Trust), Nerve Tumours UK, and the Cell and Gene Therapy Catapult to test whether CureAge's prototype can outperform MEK inhibitors on safety and tumor reduction in an animal model.
โ
"This project is an important step in generating the head-to-head evidence our field needs to move the first genetic therapy for NF1 closer to the clinic." ย Dr. Gonzalo Fernรกndez-Miranda, CEO and co-founder of CureAge Therapeutics.
โ
Matched Investment Activates the Grant
To activate the grant, CureAge secured matched private investment from the Children's Tumor Foundation, Deep Science Ventures, CureNFwithJack, Nothing is Forever e.V., and a group of angel investors, bringing the total committed to ยฃ500,000.
โ
The grant is awarded through the Innovate UK Investor Partnerships Programme, part of UK Research and Innovation (UKRI).
โ
About CureAge Therapeutics
CureAge Therapeutics, founded by the Childrenโs Tumor Foundation and Deep Science Ventures, is developing a genetic medicine platform that combines lipid nanoparticle delivery with a dual-action payload to restore NF1 gene function and eliminate residual tumor cells, with the goal of creating a scalable platform that can also benefit other peripheral nerve diseases.
โ
For more information, visit www.cureagetx.com or connect on LinkedIn.